New Biologicals for Asthma Management

New Biologicals for Asthma Management

2019 Phoenix Patient Conference: New Biologicals for Asthma
Matthew A. Rank, MD, Chair, Division of Allergy and Immunology
Mayo Clinic Arizona

Introduction of today’s topic: the new biological drugs used for asthma treatment. 00:28
Presentation overview: what it means to be biological, clinical needs and uses, asthma biologicals currently available, and their role in vasculitis. 03:11
Why do we need biological drugs for asthma? 05:37
Current asthma biological drugs: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. 08:15
How do we decide about using asthma biologics? 12:23
What about the costs of biologic drugs? 16:30
How this is all related to vasculitis: drug approvals, key studies, patients in remission, and lower dosages. 19:17
Summary slide: 5 asthma biologics now; most people with asthma won’t need them; EGPA is most relevant to mepolizumab; several additional asthma biologics in the pipeline; big need for comparative studies; not clear if biologics other than mepolizumab will be used for vasculitis. 21:30
Closing with a story about how hard the struggle is to get these medications for patients. 22:37